Comparing high altitude treatment with current best care in children with Atopic Dermatitis (AD) and asthma within the atopic syndrome by the Wilhelmina Children?s Hospital, Utrecht-Dutch Asthma Centre, DAVOS

Not Applicable

Completed

• Conditions: Atopic dermatitis and asthma within the atopic syndrome; Skin and Connective Tissue Diseases; Atopic dermatitis

• Registration Number: ISRCTN88136485
• Lead Sponsor: niversity Medical Center Utrecht (UMCU) (Netherlands)

Brief Summary

1. 2014 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/24670079 2. 2017 results in https://www.ncbi.nlm.nih.gov/pubmed/29121432 (added 31/01/2019) 3. 2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/29575251 (added 01/10/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-05-22
• Study Completion: 2015-06-01
• Last Update Posted: 29 October 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Moderate to severe atopic dermatitis
2. 8-18 years
3. Be able to speak and write in Dutch
4. Internet access and be able to use the Digital Eczema Center Utrecht
5. Willing to stay for 6 weeks in the Dutch Asthma Centre Davos

Exclusion Criteria

Current participation in another study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Current primary outcome measures as of 03/12/2013:<br> 1. Disease coping and acceptance, measured with the COPEKI/JUCCKI questionnaire<br> 2. Disease-specific quality of life, measured with Children's Dermatology Life Quality Index (CDQLI)<br> 3. Self Administered Eczema Area and Severity Index (SA-EASI)<br> All measured before the intervention, directly after the intervention, 6 weeks after the intervention and 6 months after the intervention<br><br> Previous primary outcome measures:<br> 1. Disease coping and acceptance, measured with the COPEKI/JUCCKI questionnaire directly after the intervention and 6 months after the intervention<br> 2. Disease-specific quality of life, measured with Children's Dermatology Life Quality Index (CDQLI) directly after the intervention, 6 weeks after the intervention and 6 months after the intervention<br>